Fairmount Funds Management LLC Mirati Therapeutics, Inc. Transaction History

Fairmount Funds Management LLC

  • $615 Million
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 13, 2021
SELL
$144.0 - $179.73 $9.76 Million - $12.2 Million
-67,800 Closed
0 $0
Q1 2021

May 14, 2021
BUY
$158.92 - $221.61 $1.16 Million - $1.62 Million
7,300 Added 12.07%
67,800 $11.6 Million
Q4 2020

Feb 12, 2021
BUY
$162.05 - $240.27 $4.13 Million - $6.13 Million
25,500 Added 72.86%
60,500 $13.3 Million
Q3 2020

Nov 12, 2020
BUY
$113.26 - $167.27 $3.96 Million - $5.85 Million
35,000 New
35,000 $5.81 Million

Others Institutions Holding MRTX

# of Institutions
16
Shares Held
3.57M
Call Options Held
0
Put Options Held
36.6K
View Full List

About Mirati Therapeutics, Inc.

MRTX Quotes by TradingView
  • Ticker MRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,609,800
  • Description
  • Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...
More about MRTX
Track This Portfolio

Track Fairmount Funds Management LLC Portfolio

Follow Fairmount Funds Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fairmount Funds Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fairmount Funds Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email